About the Authors
- Kerri Burgess
-
Affiliation Endocrinology and Metabolism Division, Department of Medicine, University of Rochester, Rochester, New York, United States of America
- Tianshun Xu
-
Affiliation Muscle Metabolism DPU and Platform Technology and Science, GlaxoSmithKline Research and Development, Research Triangle Park, North Carolina, United States of America
- Roger Brown
-
Affiliation Muscle Metabolism DPU and Platform Technology and Science, GlaxoSmithKline Research and Development, Research Triangle Park, North Carolina, United States of America
- Bajin Han
-
Affiliation Muscle Metabolism DPU and Platform Technology and Science, GlaxoSmithKline Research and Development, Research Triangle Park, North Carolina, United States of America
- Stephen Welle
-
* E-mail: stephen_welle@urmc.rochester.edu
Affiliation Endocrinology and Metabolism Division, Department of Medicine, University of Rochester, Rochester, New York, United States of America
Competing Interests
GlaxoSmithKline has a potential commercial interest in the metabolic effects of reducing myostatin activity. This does not alter the authors' adherence to all the PLoS ONE policies on sharing data and materials.
Author Contributions
Conceived and designed the experiments: TX RB BH SW. Performed the experiments: KB SW. Analyzed the data: KB RB SW. Contributed reagents/materials/analysis tools: TX RB BH SW. Wrote the paper: RB SW.